These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32375371)

  • 1. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
    Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
    Naughton C; O'Toole D; Kirik D; Dowd E
    Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH; Kang NH; Niles LP
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo.
    Li H; Sun B; Huang Y; Zhang J; Xu X; Shen Y; Chen Z; Yang J; Shen L; Hu Y; Gu H
    Mol Med; 2022 Mar; 28(1):29. PubMed ID: 35255803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice.
    Rocha SM; Bantle CM; Aboellail T; Chatterjee D; Smeyne RJ; Tjalkens RB
    Neurobiol Dis; 2022 Jun; 167():105685. PubMed ID: 35257879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons.
    Sharma M; Kaur J; Rakshe S; Sharma N; Khunt D; Khairnar A
    Neurotox Res; 2022 Feb; 40(1):215-229. PubMed ID: 34817799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
    Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
    J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
    Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
    Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice.
    Murakami S; Miyazaki I; Sogawa N; Miyoshi K; Asanuma M
    Neurotox Res; 2014 Oct; 26(3):285-98. PubMed ID: 24923464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Sherer TB; Kim JH; Betarbet R; Greenamyre JT
    Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics.
    Innos J; Hickey MA
    Chem Res Toxicol; 2021 May; 34(5):1223-1239. PubMed ID: 33961406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective efficacy of the glucocorticoid receptor modulator PT150 in the rotenone mouse model of Parkinson's disease.
    Latham AS; Rocha SM; McDermott CP; Reigan P; Slayden RA; Tjalkens RB
    Neurotoxicology; 2024 Jul; 103():320-334. PubMed ID: 38960072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
    Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF
    Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
    Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT
    Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
    Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.